Macrophage News and Research

RSS

A macrophage is a type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells.

Exercise transiently suppresses inflammation in rheumatic disease

Research findings presented today at the European League Against Rheumatism Annual Congress suggest that exercise transiently suppresses local and systemic inflammation, reinforcing the beneficial effects of exercise and the need for this to be regular in order to achieve clinical efficacy in rheumatic disease.

12 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Macrophages present in shed endometrium may contribute to lesion formation, shows study

A mouse model of endometriosis has been developed that produces endometriosis lesions similar to those found in humans, according to a report published in The American Journal of Pathology.

5 Jun 2014

New discovery may shed light on how common cold triggers asthma attacks

Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold.

3 Jun 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma.

2 Jun 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

Despite being touted by their manufacturers as a healthy alternative to cigarettes, e-cigarettes appear in a laboratory study to increase the virulence of drug- resistant and potentially life-threatening bacteria, while decreasing the ability of human cells to kill these bacteria

19 May 2014

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.

15 May 2014

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago.

15 May 2014

Research offers potential for future treatment of childhood acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

14 May 2014

Corneal nerve fiber assessment has potential to monitor peripheral neuropathy induced by HIV

Corneal nerve fiber assessment has great potential as a tool to diagnose and monitor peripheral neuropathy induced by HIV, say scientists at the Johns Hopkins University School of Medicine.

12 May 2014

Inflammatory pneumococcal response differs by age

The composition of inflammatory lung infiltrate in people with pneumonia caused by Streptococcus pneumoniae differs by age, an in-situ study reveals.

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

Six-way jet-in-air sorter from Beckman Coulter Life Sciences delivers simultaneous high-speed cell sorting and sub-micron particle detection

MoFlo Astrios EQ, a six-way jet-in-air sorter from Beckman Coulter Life Sciences, delivers patent pending enhanced dual forward scatter (eFSC) technology for simultaneous sorting and detection of particles from 200 nm to 30 µm in diameter. The instrument sets a new standard for flow cytometry core facilities, delivering high-speed cell sorting and micro-particle detection in a single package. Featuring detailed and precise forward scatter resolution, beadless drop sample handling and increased biosafety, Astrios EQ meets a range of analysis needs.

2 May 2014

Study shows pro-inflammatory cytokine TNF-α can speed recovery in mouse with pulmonary fibrosis

Inflammation has long been considered an integral part of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis. New research at National Jewish Health, however, suggests that a little inflammation may also be crucial to the healing and repair processes in the lungs.

26 Apr 2014

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure, and even sudden cardiac death.

22 Apr 2014

Scientists receive federal grant to track how multi-walled carbon nanotubes interact with human cells

Scientists at The University of Texas at Dallas have received a federal grant to investigate how tiny carbon structures used in the manufacture of many everyday products might affect human health.

22 Apr 2014

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept™ platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS).

10 Apr 2014

Study provides insights into why alcohol has negative effect on wound healing

People who are injured while binge drinking are much slower to heal from wounds suffered in car accidents, shootings, fires, etc.

9 Apr 2014

Macrophage News and Research

Further Reading

Exercise transiently suppresses inflammation in rheumatic disease

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Macrophages present in shed endometrium may contribute to lesion formation, shows study

New discovery may shed light on how common cold triggers asthma attacks

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

Research offers potential for future treatment of childhood acute lymphoblastic leukemia

Corneal nerve fiber assessment has potential to monitor peripheral neuropathy induced by HIV

Inflammatory pneumococcal response differs by age

Debiopharm signs new license and research agreement with Yale University

Six-way jet-in-air sorter from Beckman Coulter Life Sciences delivers simultaneous high-speed cell sorting and sub-micron particle detection

Study shows pro-inflammatory cytokine TNF-α can speed recovery in mouse with pulmonary fibrosis

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Scientists receive federal grant to track how multi-walled carbon nanotubes interact with human cells

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Study provides insights into why alcohol has negative effect on wound healing

Microbiology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo